Idorsia Ltd
SIX:IDIA

Watchlist Manager
Idorsia Ltd Logo
Idorsia Ltd
SIX:IDIA
Watchlist
Price: 1.642 CHF 5.94% Market Closed
Market Cap: 369.1m CHF

Wall Street
Price Targets

IDIA Price Targets Summary
Idorsia Ltd

Wall Street analysts forecast IDIA stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IDIA is 1.632 CHF with a low forecast of 1.01 CHF and a high forecast of 2.31 CHF.

Lowest
Price Target
1.01 CHF
38% Downside
Average
Price Target
1.632 CHF
1% Downside
Highest
Price Target
2.31 CHF
41% Upside
Idorsia Ltd Competitors:
Price Targets
4BB
4Basebio PLC
56% Upside
IVACC
Intervacc AB
572% Upside
300685
Amoy Diagnostics Co Ltd
48% Upside
BEAM
Beam Therapeutics Inc
211% Upside
4599
StemRIM Inc
120% Upside
301207
Hualan Biological Bacterin Inc
17% Upside
ORKA
Oruka Therapeutics Inc
271% Upside
300122
Chongqing Zhifei Biological Products Co Ltd
57% Upside

Revenue
Forecast

Revenue Estimate
Idorsia Ltd

For the last 7 years the compound annual growth rate for Idorsia Ltd's revenue is -5%. The projected CAGR for the next 3 years is 53%.

-5%
Past Growth
53%
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Idorsia Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Idorsia Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-36%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IDIA's stock price target?
Price Target
1.632 CHF

According to Wall Street analysts, the average 1-year price target for IDIA is 1.632 CHF with a low forecast of 1.01 CHF and a high forecast of 2.31 CHF.

What is Idorsia Ltd's Revenue forecast?
Projected CAGR
53%

For the last 7 years the compound annual growth rate for Idorsia Ltd's revenue is -5%. The projected CAGR for the next 3 years is 53%.

Back to Top